Intestinale und extraintestinale Neoplasien im Verlauf chronisch entzündlicher Darmerkrankungen : Eine Langzeitanalyse aus einem tertiären Versorgungszentrum

Zusammenfassung

Die chronisch entzündlichen Darmerkrankungen (CED) Morbus Crohn (MC) und Colitis ulcerosa (CU) weisen steigende Inzidenzraten auf. Lange Krankheitsverläufe und die Notwendigkeit immunsuppressiver Therapien bedingen Komplikationen, u.a. auch Neoplasien.

Über einen Zeitraum von 20 Jahren (2000 – 2020) wurden die Daten der Med. Klinik 2 des Klinikums Leverkusen, einem tertiären Zuweisungszentrum für chronisch entzündliche Darmerkrankungen, hinsichtlich des Auftretens maligner Erkrankungen analysiert.

In die Analyse konnten 51 Patienten eingeschlossen werden. 56 % der Neoplasien befanden sich extraintestinal, Männer waren häufiger vertreten (61 %). Patienten mit M. Crohn entwickelten häufiger extraintestinale Tumore.

Eine besondere Aufklärung von CED-Patienten über ihr Malignomrisiko scheint geboten. Dabei sollte der Fokus auf extraintestinale Malignome erweitert werden. Die Erstdiagnose einer Neoplasie bei CED-Patienten wird häufig im Alter zwischen 50 und 59 Jahren gestellt. Empfehlungen sollten bereits zum Zeitpunkt der Diagnosestellung starten und insbesondere auch Lebensstilfaktoren (z.B. Nikotinkarenz, Ernährung und Bewegung) adressieren.

Abstract

Inflammatory bowel diseases have recorded increasing incidence. A long period of illness and immunsuppressive drugs run a high risk of complications, this is particularly true for neoplasias.

Medical records of patients with inflammatory bowel diseases who developed a malignant disease during 2000 and 2020 were used for analysis.

51 patients could be included. 56% of tumors were located extraintestinal and occurred more often in patient with Crohn’s disease. Neoplasias were more frequent in men (61 %).

Individual prevention recommendations are urgently needed. Our focus should be extended to extraintestinal neoplasias. Initial diagnosis is often made in the 50+ age group. Thus, standardizised prevention programs including life-style factors should be started at the time of IBD diagnosis.

Schlüsselwörter

chronisch entzündliche Darmerkrankungen - intestinale Neoplasien - extraintestinale Neoplasien

Keywords

inflammatory bowel disease - intestinal cancer - extraintestinal cancer

Publication History

Received: 09 June 2021

Accepted after revision: 13 October 2021

Article published online:
24 November 2021

• Literatur

• 1 Molodecky NA, Soon IS, Rabi DM. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-52 DOI: 10.1053/j.gastro.2011.10.001. (PMID: 22001864)
• 2 Madanchi M, Zeitz J, Barthel C. et al. Malignancies in patients with inflammatory bowel disease: A single center experience. Digestion 2016; 94: 1-8 DOI: 10.1159/000447259. (PMID: 27318857)
• 3 Hovde O, Hoivik ML, Henriksen M. et al. Malignancies in patients with inflammatory bowel disease: Results from 20 years of follow-up in the IBSEN study. J Crohn’s Colitis 2017; 11: 571-577
• 4 Olen O, Erichsen R, Sachs MC. et al. Colorectal cancer in ulceratice colitis: a Scandinavian population-based cohort sudiy. Lancet 2020; 395: 123-131 DOI: 10.1016/S0140-6736(19)32545-0. (PMID: 31929014)
• 5 Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. NEJM 2015; 372 (15) 1441-52 DOI: 10.1056/NEJMra1403718. (PMID: 25853748)
• 6 Itzkowitz S. Colon carcinogenesis in inflammatory bowel disease: applying molecular genetics to clinical practice. J Clin Gastroenterol 2003; 36 (Suppl. 05) S70-S74 DOI: 10.1097/00004836-200305001-00012. (PMID: 12702969)
• 7 von Herbay A. Karzinome bei chronisch entzündlichen Darmerkrankungen. Der Internist 1998; 39 (10) 1024-9
• 8 Kooistra B, Dijkman B, Einhorn TA. et al. How to design a good case series. J Bone Joint Surg Am 2009; 91 (Suppl. 03) 21-6 DOI: 10.2106/JBJS.H.01573. (PMID: 19411496)
• 9 Madanchi M, Zeitz J, Barthel C. et al. Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience. Digestion 2016; 94 (01) 1-8 DOI: 10.1159/000447259. (PMID: 27318857)
• 10 Greenstein AJ, Sachar DB, Smith H. et al. Patterns of neoplasia in Crohn's disease and ulcerative colitis. Cancer 1980; 46 (02) 403-407 DOI: 10.1002/1097-0142(19800715)46:23.0.co;2-6. (PMID: 7388778)
• 11 Chang M, Chang L, Chang HM. et al. Intestinal and Extraintestinal Cancers Associated With Inflammatory Bowel Disease. Clinical colorectal cancer 2018; 170 (01) e29-e37 DOI: 10.1016/j.clcc.2017.06.009. (PMID: 28712945)
• 12 Pedersen N, Duricova D, Elkjaer M. et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 2010; 105 (07) 1480-1487 DOI: 10.1038/ajg.2009.760. (PMID: 20332773)
• 13 Taborelli M, Sozzi M, Del Zotto S. et al. Risk of intestianl and extra-intestinal cancers in patients with inflammatory bowel diseases: A population-based cohort study in northeastern Italy. PLOS ONE 2020; DOI: 10.1371/journal.pone.0235142..
• 14 Caviglia GP, Martini G, Armandi A. et al. Risk factors of urothelial cancer in inflammatory bowel disease. J Clin Med 2021; 10: 3257 DOI: 10.3390/jcm10153257. (PMID: 34362041)
• 15 Bourrier A, Carrat F, Colombel JF. et al. Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Aliment Pharmacol Ther 2016; 43: 252-261 DOI: 10.1111/apt.13466. (PMID: 26549003)
• 16 Greuter T, Vavricka S, König AO. et al. Malignancies in inflammatory bowel disease. Diegestion 2020; 100 (Suppl. 01) 136-145 DOI: 10.1159/000509544. (PMID: 32799195)
• 17 Algaba A, Guerra I, Marin-Jimenez I. et al. Incidence, management and course of cancer in patients with inflammatory bowel disease. J Crohn’s Colitis 2015; 9: 326-333
• 18 Kehren R, Zimmermann T, Adamek HE. Sportliche Aktivitäten von Patienten mit chronisch entzündlichen Darmerkrankungen. Prävention und Rehabilitation 2020; 32: 144-150
• 19 Wang Q, Zhou W. Roles and molecular mechanisms of physical exercise in cancer prevention and treatment. J Sport Health Sci 2021; 10: 201-210 DOI: 10.1016/j.jshs.2020.07.008. (PMID: 32738520)